Analysis of the Patients Who Admitted To A Turkish Emergency Department During COVID-19 Pandemic

Ertuğrul Altınbilek1, Derya Öztürk2, Ceren Atasoy3, Miray Özlem4, Fevzi Yılmaz5, Cemil Kavalci6

1İstanbul Sisli Hamidiye Etfal Education and Research Hospital, Department of Emergency Medicine, Istanbul, Turkey; 2University of Health Sciences Ankara City Hospital, Department of Emergency Medicine, Ankara, Turkey; 3İstanbul Sisli Hamidiye Etfal Education and Research Hospital, Department of Infectious Diseases, Istanbul, Turkey; 4University of Health Sciences, Ankara City Hospital, Department of Emergency Medicine, Ankara, Turkey; 5Health Sciences University, Antalya Education and Research Hospital, Department of Emergency Medicine, Antalya, Turkey; 6University of Health Sciences Diskapi Yıldırım Beyazıt Education and Research Hospital, Department of Emergency Medicine, Ankara, Turkey

Abstract: Background and aim: In this study, it was aimed to review patients who presented to a Turkish emergency department (ED) with fever and at least one symptom and finding of acute respiratory infection (cough, shortness of breath) in Sisli Hamidiye Etfal Education and Research Hospital Tertiary Medical Care Center during COVID-19 pandemic. Methods: This retrospective, descriptive, observational study included patients presented between March 10, 2020 and April 25, 2020. The patients were classified into two groups according to RT-PCR test result: RT-PCR (+) and RT-PCR (-). The demographic characteristics and clinical endpoint-related factors were analyzed in the patients. Results: The study included 840 patients; 461 men (54.9%) and 379 women (45.1%). RT-PCR test was positive in 345 patients (41.0%). The most common comorbidity was hypertension (HT) in 119 patients (34.5%); followed by diabetes mellitus (DM) in 61 patients (18.3%). At time of ED presentation, there was mild clinical manifestation in 72.2%, whereas moderate in 21.7% and severe in 6.1% of patients with positive RT-PCR testing. Of the patients with positive RT-PCR testing, 64 patients (18.6%) were discharged from ED while 255 patients (73.9%) were admitted to COVID clinic and 26 were admitted to COVID intensive care unit (ICU). Of the patients admitted, 299 patients (86.7%) were discharged while 46 patients (13.3%) died due to multi-organ failure (MOF) (50%), acute respiratory distress syndrome (ARDS) (32.6%), acute pulmonary embolism (APE) (10.9%) and acute coronary syndrome (ACS) (6.5%).

Conclusions: The RT-PCR positivity rate seemed lower in our study when compared to literature. In addition, mortality rate was lower in our study when compared to other countries.

Keywords: COVID-19, RT-PCR, Emergency Department

Introduction

Initially, Zhu et al. reported a disease with unknown etiology which can cause pneumonia, ARDS or even death in Wuhan City of Hubei Province, China on December 31, 2019 (1). On January 7, 2020, it was found that the causative agent is a novel coronavirus (2019-nCoV) which hasn’t been detected in human so far. Subsequently, the disease was designated as Coronavirus disease-19 (COVID-19) and causative agent as SARS-Cov2 (2). It was reported that SARS-Cov2 belongs to coronavirus family and causes a clinical presentation similar to Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS) pandemics (1). It was proposed that the primary host is bats and that it could be transmitted to human from intermediate host, pangolins (3). The major feature of SARS-Cov2 is high infectivity. It is primarily transmitted through droplets occurring during cough, sneezing or speech.
On January 30, 2020, the World Health Organization (WHO) designated outbreak as international public health emergency. On March 11, 2020, WHO finally declared outbreak as pandemics given severity and viral spread in 113 country (4). On March 11, 2020, the first case was announced in Turkey by Health Ministry. During this period, many hospitals across Turkey were designated as Pandemic Hospital (5).

Because of the disease, governments have taken drastic measures like the quarantine of hundreds of millions of people worldwide. However, due to the large number of asymptomatic cases of COVID-19, these efforts are limited to the problem of discriminating between COVID-19 positive and negative individuals (6). In this study, it was aimed to assess demographic characteristics and clinical outcome in patients stratified as positive or negative according to RT-PCR result.

Methods

Eight hundred forty patients were included in this retrospective observational study. The study included patients who presented with fever and at least one symptom or finding of acute respiratory tract infection (cough, shortness of breath) to ED of Sisli Hamidiye Etfal Education and Research Hospital between March 10, 2020 and April 25, 2020 and underwent RT-PCR testing from nasopharynx and oropharynx as they fulfilled possible case definition for COVID-19. This study was approved by the Ethics Committee of the Health Science University Şişli Hamidiye Etfal Education and Research Hospital in Istanbul (approval number: 2760).

Patients older than 18 years of age who had symptoms (fever and respiratory symptoms such as cough and acute respiratory failure) of COVID-19 and who admitted to the ED were included in the study. Exclusion criteria were age <18 years old, patients with missing data and patients referred to another center. The diagnosis of SARS-CoV-2 was confirmed by RT-PCR in the nasopharyngeal and oropharyngeal swap samples. Only one nasopharyngeal (NP) and oropharyngeal (OP) swap sample was obtained from the patients with negative RT-PCR results and without any indication of hospitalization in accordance with the guidelines of Turkish Ministry of Health and WHO and their follow up were conducted in accordance with these guidelines (7,8). The NP and OP swap samples were obtained by a special team including the specialists in microbiology and general practitioners.

Age, gender, emergency admission date, travel history, occupation, additional disease, ICU admission, length of hospital stay, mortality (survival or non-survival) data, and COVID-19 PCR results were scanned from the hospital automation system. Patients were divided into two groups as RT-PCR test result positive RT-PCR (+) and negative RT-PCR (-).

Clinical manifestations of the were classified according to the indications by the National Institutes of Health adopted from these indications (9). Mild cases were the patients who did not have pneumonia findings in computed tomography (CT) and that could be followed without hospitalization, mild cases were the patients who had pneumonia findings in CT and had fewer and respiratory symptoms and severe cases were the patients with dyspnea, respiratory frequency < 30 breaths per minute, SpO₂ < 93%, PaO₂ / FiO₂ < 300 and / or lung infiltrates > 50%.

Statistical Evaluation

Normally and abnormally distributed quantitative variables were compared using the Student’s t test and the Mann-Whitney U test, respectively. Categorical variables were compared using the chi-square test. The results were given as the mean and standard deviation, median and interquartile range or frequency and percentage, wherever appropriate. Categorical and consecutive variables were evaluated by univariate logistic regression analysis for their ability to predict mortality. A P value of < .05 was considered statistically significant. Statistical analyses were performed using SPSS version 26.0.

Results

The study included 840 patients (461 men (54.9%) and 379 women (45.1%) without missing data who presented to ED with fever and at least one symptom
Analysis of the patients who admitted to a Turkish emergency department during COVID-19 pandemic

or finding of acute respiratory tract infection (cough, shortness of breath) and underwent RT-PCR testing as they fulfilled possible case definition. When patients were assessed according to confirmation by RT-PCR test, it was found that RT-PCR testing was positive in 345 patients (41.0%) while negative in 495 patients (59.0%). Mean age was significantly higher in RT-PCR (+) patients (55.5±17.3 years) compared to RT-PCR (-) patients (49.7±18.4 years) (p<0.05) (Table 1, Figure 1). RT-PCR(-) patients who were confirmed to have COVID-19 with CT findings and clinical manifestation received the treatment. In RT-PCR(+) cases, treatment was initiated immediately. Both patient groups that were confirmed to have COVID-19 received hydroxychloroquine. Depending on the clinical prognosis, patients received favipiravir and in case of clinical picture gets worsen prognosis, patients received immune plasma treatment.

Of the RT-PCR (+) patients, 60.3% were men and 39.7% were women. There was significantly more male patients in RT-PCR (+) group compared to PCR-RT (-) group (p<0.05). There was history of foreign travel within prior 14 days in 2.0% of RT-PCR (+) patients and in 1.6% of RT-PCR (-) patients, indicating no significant difference between groups (p>0.05). Of the cases, 24.1% (n=108) were healthcare providers. The RT-PCR test was positive in 24.0% whereas negative in 76.0% of patients working at healthcare services. The proportion of healthcare providers were significantly lower in RT-PCR (+) group when compared to RT-PCR (-) group (p<0.05). When assessed regarding medication, the most common drugs used were anti-hypertensive agents by 33.9% and anti-diabetic agents by 17.1%. The rates of medication, anti-hypertensive use and anti-diabetic use were significantly higher in RT-PCR (+) group than RT-PCR (-) group (p<0.05); however, there was no significant difference in analgesic, anticoagulant, anti-arrhythmic agent and bronchodilator use (p>0.05) (Table 1).

When comorbidity was assessed, it was found that there was a comorbid disease in 51.6% of RT-PCR (+) patients whereas in 38.8% of RT-PCR (-) patients. The most common comorbidity was HT by 34.5%; followed DM by 18.3%. The rates of comorbidity, HT, DM and malignancy were significantly higher in RT-PCR (+) group than RT-PCR (-) group (p<0.05); however, there was no significant difference in coronary artery disease (CAD), chronic obstructive pulmonary disease (COPD), chronic renal failure (CRF) and thyroid disease between RT-PCR (+) and RT-PCR (-) groups (p>0.05) (Figure 2).

![Figure 1: Age distribution of RT-PCR(+) and RT-PCR(-) patients](image)

![Figure 2: Analysis of comorbidities in RT-PCR(+) and RT-PCR(-) patients](image)

There was CT finding compatible with viral pneumonia in 245 (71%) of RT-PCR (+) patients and 283 (57.2%) of RT-PCR (-) patients. The incidence of CT finding compatible viral pneumonia was significantly higher in RT-PCR (+) group compared to RT-PCR (-) group (p<0.05). At time of ED presentation, there was a mild in 72.2%, moderate in 21.7% and severe clinical manifestation in 6.1% of patients with positive RT-PCR test results. On the other hand, mild clinical manifestation was observed in 81.4%, moderate in 14.7% and severe in 3.9% patients with negative RT-PCR test results. The clinical manifestation at ED presentation was significantly more severe in RT-PCR (+) group compared to RT-PCR (-) group (p<0.05).

Regarding clinical outcome, 18.6% of RT-PCR (+) patients were discharged from ED, while 73.9% were admitted to COVID-19 clinic and 7.5% to COVID-19 intensive care unit. Mean length of hospital stay was 7.7±6.7 days in RT-PCR (+) group. Of RT-PCR (-) patients, 38.8% were discharged from ED while 57.0% were admitted to clinic and 4.2% to ICU. Mean length of hospital stay was 4.3±4.8 days in RT-PCR (-) group. The disposition rate was significantly lower in RT-PCR (+) group compared to
Table 1. Analysis of patients with positive or negative RT-PCR testing

|                      | PCR (-) |                      | PCR (+) |                      | P   |
|----------------------|---------|----------------------|---------|----------------------|-----|
|                      | Mean ± SD /n-% | Median | Mean ± SD /n-% | Median |       |
| Age                  | 49.7 ± 18.4 | 48.0 | 55.5 ± 17.3 | 55.0 | 0.000 m |
| Gender               |          |       |            |       |       |
| Male                 | 253      | 51.1% | 208       | 60.3% | 0.009 \(\chi^2\) |
| Female               | 242      | 48.9% | 137       | 39.7% |       |
| Travel History       |          |       |            |       |       |
| -                    | 487      | 98.4% | 338       | 98.0% | 0.662 \(\chi^2\) |
| +                    | 8        | 1.6%  | 7         | 2.0%  |       |
| Occupation           |          |       |            |       |       |
| Healthcare services  | 82       | 16.6% | 26        | 7.5%  | 0.000 \(\chi^2\) |
| Non-healthcare services | 413       | 83.4% | 319       | 92.5% |       |
| Medication           |          |       |            |       |       |
| (+)                  | 177      | 35.8% | 171       | 49.6% | 0.000 \(\chi^2\) |
| (-)                  | 318      | 64.2% | 174       | 50.4% |       |
| Anti-hypertensive    | 121      | 24.4% | 117       | 33.9% | 0.003 \(\chi^2\) |
| Anti-diabetic        | 57       | 11.5% | 59        | 17.1% | 0.021 \(\chi^2\) |
| Analgesics           | 5        | 1.0%  | 7         | 2.0%  | 0.221 \(\chi^2\) |
| Anticoagulant        | 56       | 11.3% | 43        | 12.5% | 0.611 \(\chi^2\) |
| Anti-arrhythmic      | 47       | 9.5%  | 33        | 9.6%  | 0.973 \(\chi^2\) |
| Bronchodilator       | 31       | 6.3%  | 23        | 6.7%  | 0.814 \(\chi^2\) |
| Other                | 55       | 11.1% | 46        | 13.3% | 0.330 \(\chi^2\) |
| Comorbid disease     |          |       |            |       |       |
| (+)                  | 192      | 38.8% | 178       | 51.6% | 0.000 \(\chi^2\) |
| (-)                  | 303      | 61.2% | 167       | 48.4% |       |
| Hypertension         | 113      | 22.8% | 119       | 34.5% | 0.000 \(\chi^2\) |
| CAD                  | 51       | 10.3% | 50        | 14.5% | 0.066 \(\chi^2\) |
| DM                   | 59       | 11.9% | 63        | 18.3% | 0.010 \(\chi^2\) |
| COPD                 | 36       | 7.3%  | 26        | 7.5%  | 0.886 \(\chi^2\) |
| CRH                  | 17       | 3.4%  | 12        | 3.5%  | 0.973 \(\chi^2\) |
| Thyroid disease      | 11       | 2.2%  | 8         | 2.3%  | 0.926 \(\chi^2\) |
| CA                   | 3        | 0.6%  | 9         | 2.6%  | 0.016 \(\chi^2\) |
| Other                | 26       | 5.3%  | 29        | 8.4%  | 0.069 \(\chi^2\) |
| Pneumonia            |          |       |            |       |       |
| (+)                  | 283      | 57.2% | 245       | 71.0% | 0.000 \(\chi^2\) |
| (-)                  | 212      | 42.8% | 100       | 29.0% |       |
| General health status at ED presentation |          |       |            |       |       |
| Mild                 | 403      | 81.4% | 249       | 72.2% |       |
| Moderate             | 73       | 14.7% | 73        | 21.2% |       |
| Severe               | 17       | 3.4%  | 23        | 6.7%  | 0.006 \(\chi^2\) |
| Length of hospital stay | 4.3 ± 4.8 | 4.0 | 7.7 ± 6.7 | 7.0 | 0.000 m |
| Clinical outcome     |          |       |            |       |       |
| Discharge            | 474      | 95.8% | 299       | 86.7% | 0.000 \(\chi^2\) |
| Death                | 21       | 4.2%  | 46        | 13.3% |       |

(continued)
RT-PCR (-) group (p<0.05). In addition, mean length of hospital stay was significantly longer in RT-PCR (+) group when compared to RT-PCR (-) group (p<0.05). Twenty-one patients with negative RT-PCR results (4.2%) underwent noninvasive ventilation, continuous positive airway pressure or intubation. On the other hand, 26 patients with positive RT-PCR results (7.5%) underwent noninvasive ventilation, continuous positive airway pressure or intubation. In RT-PCR (+) group, 86.7% of patients admitted were discharged while 13.3% died. In RT-PCR (-) group, 95.8% of patients admitted were discharged while 4.2% died. The mortality rate was significantly higher in RT-PCR (+) group than RT-PCR (-) group (p<0.05). Among these patients, 23 of them died due to MOF, 15 of them died ARDS, five of them died due to APE, and three of them died due to ACS.

Discussion

COVID-19 epidemiology can show variations across countries. It is proposed that the variation in epidemiology results from factors including genetic, demographic and sociocultural characteristics, diversity of healthcare services, control strategies for pandemic, differences in treatment and epidemiological data. In a study from Italy, Spina et al. showed effects of healthcare services on spread of the disease. In addition, Lu et al. showed that clinical severity might differ in cases with diverse genomic characteristics (10, 11). There are several reports indicating different outcomes regarding prevalence and severity of COVID-19 infection (12). In our study, we retrospectively reviewed included 840 patients who presented to a tertiary emergency department in the biggest city of Turkey with fever and at least one symptom or finding of acute respiratory tract infection (cough, shortness of breath) and underwent RT-PCR testing as they fulfilled possible case definition; the RT-PCR positivity rate was 41% in the series. In a study on 51 patients, Fang et al. reported RT-PCR positivity rate as 71% (13). The reason for this low ratio might be attributed to that even though repeated sampling has been done on the patients with negative RT-PCR results, the initial RT-PCR positivity was taken into the account while conducting the study. In a study by Cai et al., it was found that positivity rate was higher among male patients. In another study from China, it was reported that 58% of cases were male. In another study, it was shown that there was no gender preponderance but clinical picture was more severe in male patients (14, 15). In our study, mean age was 55.5±17.3 years and 60.3% were men in agreement with literature.

In our study, 18.6% of RT-PCR (+) patients were discharged by recommendation of isolation while 73.9% were admitted to COVID-19 clinic and 7.5% to COVID-19 ICU. Mean length of hospital stay was 7.7±6.7 days. In a Chinese study by Zhou et al., chronic HT and / or DM was frequently observed in case series (16-20). In addition, in a meta-analysis (including 7 studies, Yang et al. demonstrated that most common comorbidities were HT and DM (11). In our study, we assessed comorbidity and medications in RT-PCR (+) patients. The most common comorbidity was HT by 34.5% while the most common drug class was anti-hypertensive agents by 33.9%).

In a report by Chinese Center for Disease Control and Prevention, clinical course was mild 81% and moderate in 14% of cases while 5% were critically ill.
In the study by Fang et al., CT showed positive findings in 98% of patients with positive RT-PCR testing (13-17). In our study, at time of ED presentation, there was mild clinical manifestation in 72.2% whereas moderate in 21.7% and severe in 6.1% of patients with positive RT-PCR testing. In addition, 71% of patients had CT findings compatible with COVID-19 disease. Liu et al. attributed variations in clinical course to viral load in addition to individual characteristics (16). The healthcare providers exposed highest viral load during pandemics. In our study, RT-PCR (+) positivity rate was 7.5% in healthcare providers but no mortality was observed.

In a study from, in-hospital mortality was reported as 15%. In another study from US, in-hospital mortality was reported as 21%. Liang et al. reported a mortality rate of 3.2% (18-22). The comorbidity incidence was 25.1% (15-17). In our study, there was a comorbid condition in 51.6% of RT-PCR (+) patients and mortality rate was 13.3% in this group. In our study, lower mortality rate was observed when compared to the studies with similar comorbidity rate in the literature, concluding that comorbidity is one of the major factors determining mortality. There was a comorbid condition in RT-PCR (-) patients and mortality rate was 4.2% in this group.

Conclusions

Although sample size was sufficient, RT-PCR positivity rate seemed lower than literature. Studies on larger samples can be helpful in this issue. In addition, mortality rate was lower compared to literature. It may be due to lower mean age of population and lifestyle habits such as smoking habits of the patients.

Author Contributions

Conception and design of the research: Altınbilek E, Öztürk D, Atasoy C; Acquisition of data: Altınbilek E, Özlem M; Analysis and interpretation of the data: Yılmaz F, Kavalcı C; Writing of the manuscript: Altınbilek E, Özlem M, Yılmaz F; Critical revision of the manuscript for important intellectual content: Yılmaz F, Kavalcı C, Altınbilek E.

Acknowledgments

We are deeply indebted to all our colleagues for their understanding and cooperation.

Informed Consent

All patients provided written informed consent prior to study participation.

Financial Disclosure

The authors declare that the research did not receive specific funding.

Conflict of Interest

“Each author declares that he or she has no commercial associations (e. g. consultancies, stock ownership, equity interest, patent/licensing arrangement etc.) that might pose a conflict of interest in connection with the submitted article”.

References

1. Zhu N, Zhang D, Wang W Li X, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Eng J Med 2020; 382(8): 727-33. doi: 10.1056/NEJMoa2001017.
2. World Health Organization (2020) Novel coronavirus (2019-nCoV). Situation Report 22. 11 February 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200211-sitrep-22-ncov.pdf?sfvrsn=fb6d49b1_2 (accessed 15 july 2020).
3. Rothan, H.A, Byrareddy SN. The Epidemiology and Pathogenesis of Coronavirus Disease (COVID-19) Outbreak. J Autoimmun 2020; 109: 102433. doi: 10.1016/j.jaut.2020.102433. Epub 2020 Feb 26.
4. World Health Organization (2020) Novel Coronavirus (2019-nCoV). Situation Report 11. 31 January 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200131-sitrep-11-ncov.pdf?sfvrsn=de7c0f7_4 (accessed 15 july 2020).
5. Republic of Turkey Ministry of Health Corona Table Retrieved from; https://covid19.saglik.gov.tr/ (2020); Accessed May 13, 2020
6. Day M. Covid-19: identifying and isolating asymptomatic people helped eliminate virus in Italian village. BMJ 2020; 368:m1165. doi: 10.1136/bmj.m1165.
Analysis of the patients who admitted to a Turkish emergency department during COVID-19 pandemic

7. Demirbilek Y, Pehlivantürk G, Özgüler Z.O, Alp Meşe E; Covid-19 Outbreak Control, Example Of Ministry Of Health Of Turkey; Turk J Med Sci 2020; 50: 489–494.

8. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Last Updated: Testing for SARS-CoV-2 Infection; July 17, 2020; https://www.covid19treatmentguidelines.nih.gov/overview/sars-cov-2-testing/.

9. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Last Updated: Management of Persons with COVID-19; Last Updated: June 11, 2020; https://www.covid19treatmentguidelines.nih.gov/overview/management-of-covid-19/.

10. Spina S, Marrazzo F, Migliari M, Stucchi R, Sforza A, Fumagalli R. The response of Milan’s Emergency Medical System to the COVID-19 Outbreak in Italy. Lancet 2020; 395(10227): e49-e50. doi: 10.1016/S0140-6736(20)30493-1. Epub 2020 Feb 28.

11. Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis 2020; 94: 91-95. doi: 10.1016/j.ijid.2020.03.017. Epub 2020 Mar 12.

12. Guan W, Ni Z, Liang W, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382(18):1708-1720. doi: 10.1056/NEJMoa200232. Epub 2020 Feb 28.

13. Fang Y, Zhang H, Xie X, et al. Sensitivity of Chest CT for COVID-19: Comparison to RT-PCR. Radiology 2020; 200432. doi: 10.1148/radiol.2020200432. Online ahead of print.

14. Cai H. Sex difference and smoking predisposition in patients with COVID-19. Lancet Respir Med 2020; 8(4):e20. doi: 10.1016/S2213-2600(20)30117-X. Epub 2020 Mar 11.

15. Zhang JJ, Dong X, Cao Y, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020; 75(7):1730-1741. doi: 10.1111/all.14238. Epub 2020 Feb 27.

16. Liu Y, Yan L, Wan L, et al. Viral dynamics in mild and severe cases of COVID-19. The Lancet Infect Dis 2020; 20(6): 656-657. doi: 10.1016/S1473-3099(20)30232-2. Epub 2020 Mar 19.

17. Li Q, Guan X, Wu P, et al. N Engl J Med 2020;382(13):1199-1207. doi: 10.1056/NEJMoa2001316. Epub 2020 Jan.

18. Liang, W.H., et al., Clinical characteristics and outcomes of hospitalized patients with COVID-19 treated in Hubei (epicenter) and outside Hubei (non-epicenter): A Nationwide Analysis of China. Eur Respir J 2020; 55(6): 2000562. doi: 10.1183/13993003.00562-2020. Print 2020 Jun.

19. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA 2020; 323(20): 2052-2059. doi: 10.1001/jama.2020.6775.

20. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395(10229): 1054-1062. doi: 10.1016/S0140-6736(20)30566-3.

21. Jian-Min Jin JM, Bai P He W, et al. Gender Differences in Patients With COVID-19: Focus on Severity and Mortality. Front Public Health 2020; 8:152. doi.org/10.3389/fpubh.2020.00152. eCollection 2020.

22. Lu R, Zhao X, Li J, et al. Genomic Characterisation And Epidemiology Of 2019 Novel Coronavirus: Implications For Virus Origins And Receptor Binding; Lancet 2020; 395(10224): 565-574. doi: 10.1016/S0140-6736(20)30251-8. Epub 2020 Jan 30.

Received: 1 August 2020
Accepted: 7 October 2020
Correspondence:
Ertuğrul Altınbilek, MD, Istanbul Sisli Hamidiye Etfal Education and Research Hospital, Department of Emergency Medicine, Istanbul, Turkey
Phone: +90 5059046833
Fax: +90 212 224 07 72
Email: ertugrulaltinbilek@gmail.com